<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Collplant Biotechnologies Ltd — News on 6ix</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd</link>
<description>Latest news and press releases for Collplant Biotechnologies Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/collplant-biotechnologies-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835564d78dffbe2df0e9acc.webp</url>
<title>Collplant Biotechnologies Ltd</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd</link>
</image>
<item>
<title>COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-reports-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-reports-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative</description>
</item>
<item>
<title>CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-receives-nasdaq-notification-regarding-minimum-bid-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-receives-nasdaq-notification-regarding-minimum-bid-requirement</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>REHOVOT, Israel, March 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative</description>
</item>
<item>
<title>CollPlant Biotechnologies Launches Redesigned Corporate Website</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-launches-redesigned-corporate-website</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-launches-redesigned-corporate-website</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>REHOVOT, Israel, March 18, 2026 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and</description>
</item>
<item>
<title>COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-date-for-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-date-for-full-year-2025-financial-results</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>REHOVOT, Israel, March 11, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative</description>
</item>
<item>
<title>CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-korean-patent-allowance-secured-for-its-photocurable-dermal-filler</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-korean-patent-allowance-secured-for-its-photocurable-dermal-filler</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product CandidateREHOVOT, Israel, Feb. 26, 2026 /PRNewswire/ --</description>
</item>
<item>
<title>CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-elevates-rhcollagen-3d-bioprinting-portfolio-with-launch-of-ready-to-print-bioflex</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-elevates-rhcollagen-3d-bioprinting-portfolio-with-launch-of-ready-to-print-bioflex</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic PerformanceBioFlex Expands CollPlant's Animal-Free Bioink</description>
</item>
<item>
<title>CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-targets-aesthetic-market-driven-120000413</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-targets-aesthetic-market-driven-120000413</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with GLP-1 therapies.</description>
</item>
<item>
<title>COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-2-0-130000665</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-2-0-130000665</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,600,000 of the Company's ordinary shares at a purchase price of $1.25 per share in a registered direct offering. In addition, in a concurrent private placement,</description>
</item>
<item>
<title>COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-reports-2025-third-123000592</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-reports-2025-third-123000592</guid>
<pubDate>Wed, 26 Nov 2025 12:30:00 GMT</pubDate>
<description>CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter of 2025 and provided a corporate update.</description>
</item>
<item>
<title>COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-date-2025-120000015</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-date-2025-120000015</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, before the opening of the U.S. financial markets.</description>
</item>
<item>
<title>CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-expands-rhcollagen-distribution-capabilities-110000411</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-expands-rhcollagen-distribution-capabilities-110000411</guid>
<pubDate>Mon, 27 Oct 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the expansion of its distribution footprint into North America through a new partnership with a U.S.-based logistics center. Scheduled to become operational this quarter, the logistics hub will provide full cGMP-compliant storage and distribution services and will serve as a clinic</description>
</item>
<item>
<title>CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplants-rhcollagen-based-bioink-demonstrates-110000723</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplants-rhcollagen-based-bioink-demonstrates-110000723</guid>
<pubDate>Mon, 20 Oct 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced positive results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D™, and Matrigel®, conducted by the Levenberg Lab at Technion - Israel Institute of Technology.</description>
</item>
<item>
<title>First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/first-kind-fully-humanized-3d-110000551</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/first-kind-fully-humanized-3d-110000551</guid>
<pubDate>Thu, 16 Oct 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary, non-animal recombinant human collagen (rhCollagen), today announced that, according to a scientific article published in the Archives of Dermatological Research, researchers from Mayo Clinic have developed the first fully humanized 3D bioprinted skin model using CollPlant's plant-derived rhCollagen. The model represents an innovative al</description>
</item>
<item>
<title>CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-positive-results-110000889</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-positive-results-110000889</guid>
<pubDate>Tue, 30 Sep 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human collagen (rhCollagen), today announced positive results from its non-clinical program evaluating its photocurable dermal filler, as well as plans to advance this product candidate into clinical trials. This novel filler represents a significant breakthrough in aesthetic medicine by uniquely integrating contou</description>
</item>
<item>
<title>CollPlant Expands the Distribution of its VergenixSTR Product in Europe</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-expands-distribution-vergenixstr-product-110000498</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-expands-distribution-vergenixstr-product-110000498</guid>
<pubDate>Mon, 15 Sep 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its European distribution network for Vergenix™ STR through the signing of a new agreement in Poland. Vergenix™STR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting</description>
</item>
<item>
<title>CollPlant to Present at the 2025 International Conference on Biofabrication</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-present-2025-international-conference-110000827</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-present-2025-international-conference-110000827</guid>
<pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced its participation in the annual meeting of The International Society of Biofabrication: the International Conference on Biofabrication 2025, to be held September 14–17, 2025, at the Palace of Culture and Science in Warsaw, Poland.</description>
</item>
<item>
<title>CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-participate-upcoming-27th-annual-110000554</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-participate-upcoming-27th-annual-110000554</guid>
<pubDate>Mon, 25 Aug 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference on Monday, September 8th and Tuesday September 9th, 2025, at the Lotte New York Palace Hotel.</description>
</item>
<item>
<title>COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-reports-2025-second-110000023</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-reports-2025-second-110000023</guid>
<pubDate>Wed, 20 Aug 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter of 2025 and provided a corporate update.</description>
</item>
<item>
<title>COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-date-second-110000092</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-biotechnologies-announces-date-second-110000092</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets.</description>
</item>
<item>
<title>CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations</title>
<link>https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-appoints-collagen-biomaterials-expert-110000623</link>
<guid isPermaLink="true">https://6ix.com/company/collplant-biotechnologies-ltd/news/collplant-appoints-collagen-biomaterials-expert-110000623</guid>
<pubDate>Mon, 14 Jul 2025 11:00:00 GMT</pubDate>
<description>CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for Co</description>
</item>
</channel>
</rss>